Centessa Pharmaceuticals plc (CNTA) Form 8-K — Jun 24, 2026
Centessa Pharmaceuticals plc has completed its acquisition by Eli Lilly and Company through a scheme of arrangement. Shareholders are entitled to receive $38.00 in cash per share along with a contingent value right worth up to an additional $9.00 per share contingent upon the achievement of specified milestones. As a result of the transaction, Centessa has requested the delisting of its American Depositary Shares from the Nasdaq Stock Market. The company also repaid all indebtedness under its loan agreement with Oxford Finance LLC and terminated its ATM sales agreement with Leerink Partners LLC.
Key figures
- Cvr Max Value Per Share
- $9.00
- Cash Consideration Per Share
- $38.00
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.